% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Hawkins:893882,
      author       = {Hawkins, Peter C. T. and Zelaya, Fernando O. and O'Daly,
                      Owen and Holiga, Stefan and Dukart, Jürgen and Umbricht,
                      Daniel and Mehta, Mitul A.},
      title        = {{T}he effect of risperidone on reward‐related brain
                      activity is robust to drug‐induced vascular changes},
      journal      = {Human brain mapping},
      volume       = {42},
      number       = {9},
      issn         = {1097-0193},
      address      = {New York, NY},
      publisher    = {Wiley-Liss},
      reportid     = {FZJ-2021-02894},
      pages        = {2766 - 2777},
      year         = {2021},
      abstract     = {Dopamine (DA) mediated brain activity is intimately linked
                      to reward-driven cerebralresponses, while aberrant reward
                      processing has been implicated in several
                      psychiatricdisorders. fMRI has been a valuable tool in
                      understanding the mechanism by which DAmodulators alter
                      reward-driven responses and how they may exert their
                      therapeuticeffect. However, the potential effects of a
                      pharmacological compound on aspects ofneurovascular coupling
                      may cloud the interpretability of the BOLD contrast. Here,
                      weassess the effects of risperidone on reward driven BOLD
                      signals produced by rewardanticipation and outcome, while
                      attempting to control for potential drug effects onregional
                      cerebral blood flow (CBF) and cerebrovascular reactivity
                      (CVR). Healthy malevolunteers (n = 21) each received a
                      single oral dose of either 0.5 mg, 2 mg of risperi-done or
                      placebo in a double-blind, placebo-controlled, randomised,
                      three-period cross-over study design. Participants underwent
                      fMRI scanning while performing the widelyused Monetary
                      Incentive Delay (MID) task to assess drug impact on reward
                      function.Measures of CBF (Arterial Spin Labelling) and
                      breath-hold challenge induced BOLD sig-nal changes (as a
                      proxy for CVR) were also acquired and included as
                      covariates. Risperi-done produced divergent, dose-dependent
                      effects on separate phases of rewardprocessing, even after
                      controlling for potential nonneuronal influences on the
                      BOLDsignal. These data suggest the D2 antagonist risperidone
                      has a wide-ranging influenceon DA-mediated reward function
                      independent of nonneuronal factors. We also illus-trate that
                      assessment of potential vascular confounds on the BOLD
                      signal may beadvantageous when investigating CNS drug action
                      and advocate for the inclusion ofthese additional measures
                      into future study designs.},
      cin          = {INM-7},
      ddc          = {610},
      cid          = {I:(DE-Juel1)INM-7-20090406},
      pnm          = {5253 - Neuroimaging (POF4-525)},
      pid          = {G:(DE-HGF)POF4-5253},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {33666305},
      UT           = {WOS:000625860700001},
      doi          = {10.1002/hbm.25400},
      url          = {https://juser.fz-juelich.de/record/893882},
}